ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: AMA Opposes Bill To Permit Heroin Use For Pain Control, Says Morphine Is Equally As Effective

March 23, 1984

ACS Supports NCI’s Bypass Budget In Resolution

March 20, 1992

Center Directors Solidly opposed To Core grant changes, Ask Upton, NCAB To Find Other Solutions

November 11, 1977

Buenos Aires Academy Denies Argentina Prosecutes Scientist

July 28, 1978

In Brief: RFP Offers Patent Rights Instead Of Profit; ACS, NCI Plan More Joint Projects; BC Report Sept. 30

September 20, 1974

CDC study finds obesity may become leading preventable cause of death; NIH research plan drafted.

March 26, 2004